Flying The Web For News.
  • Career Exam Study
    Career Exam Study
  • US Politics
    US Politics
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News

Article Tools/Herramientas de artículos

+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeña




Globe NewsWire News Distribution Service


FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present data from multiple investigational studies for its first-in-class treatment VOQUEZNA® (vonoprazan) tablets at the American College of Gastroenterology (ACG) 2024…


Posted: 2024-10-27 16:00:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



Related Bing News Search Results

Press Release: Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting - Newscast

Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target Lowered to $12.00 at The Goldman Sachs Group

Mon, 10 Mar 2025 23:40:00 GMT Phathom Pharmaceuticals (NASDAQ:PHAT – Free Report) had its price objective reduced by The Goldman Sachs Group from $18.00 to $12.00 in a research report sent to investors on Monday morning,Benzinga ...

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript

Thu, 06 Mar 2025 09:13:00 GMT Hello, and welcome to the Phathom Pharmaceuticals Fourth Quarter and ... Earlier this morning, we issued a press release detailing the results we will be discussing during the call.

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Thu, 06 Mar 2025 04:30:00 GMT VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 ...

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates

Thu, 06 Mar 2025 01:10:00 GMT Ahead of this earnings release, the estimate revisions trend for Phathom Pharmaceuticals: mixed. While the magnitude and direction of estimate revisions could change following the company's ...

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Wed, 05 Mar 2025 21:00:00 GMT FLORHAM PARK, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals ... Non-GAAP Financial Measures This press release includes financial results prepared in accordance with accounting ...
Blow Us A Whistle




Related Product Search/Búsqueda de productos relacionados